The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Capturing uveal melanoma (UM) global practice patterns and clinical outcomes in the collaborative ocular melanoma natural history (OMNi) study (NCT04588662).
 
Joseph J. Sacco
Honoraria - Immunocore; Novartis; Pierre Fabre
Consulting or Advisory Role - BMS; Delcath Systems; Immunocore; Immunocore (Inst); MSD
Research Funding - AstraZeneca (Inst); BMS (Inst); Immunocore (Inst); Replimune (Inst)
Travel, Accommodations, Expenses - BMS; MSD
 
Marlana M. Orloff
Consulting or Advisory Role - IDEAYA Biosciences; Immunocore; TriSalus Life Sciences
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb (Inst); Delcath Systems (Inst); IDEAYA Biosciences (Inst); IDEAYA Biosciences (Inst); Immunocore (Inst); Linnaeus Therapeutics (Inst); Plexxikon (Inst)
 
Sapna Pradyuman Patel
Honoraria - Delcath Systems; Immunocore; Merck
Consulting or Advisory Role - Castle Biosciences; TriSalus Life Sciences
Research Funding - Bristol-Myers Squibb (Inst); Deciphera (Inst); Foghorn Therapeutics (Inst); InxMed (Inst); Lyvgen Biopharma (Inst); Novartis (Inst); Provectus (Inst); Reata Pharmaceuticals (Inst); Seagen (Inst); Syntrix Biosystems (Inst); TriSalus Life Sciences (Inst)
Travel, Accommodations, Expenses - TriSalus Life Sciences
Other Relationship - Immunocore
 
Max Conway
No Relationships to Disclose
 
Li-Anne Lim
No Relationships to Disclose
 
Lotte S. Fog
No Relationships to Disclose
 
David Sia
No Relationships to Disclose
 
John McKenzie
No Relationships to Disclose
 
Daniel McKay
No Relationships to Disclose
 
Roderick O'day
No Relationships to Disclose
 
Timothy Isaacs
No Relationships to Disclose
 
Alexander Noor Shoushtari
Consulting or Advisory Role - Bristol-Myers Squibb; Immunocore; Novartis
Research Funding - Bristol-Myers Squibb; Checkmate Pharmaceuticals (Inst); Foghorn Therapeutics (Inst); Immunocore; Novartis (Inst); Pfizer (Inst); Polaris; Targovax (Inst); Xcovery
Patents, Royalties, Other Intellectual Property - UpToDate
 
Ryan J. Sullivan
Consulting or Advisory Role - alkermes; Asana Biosciences; AstraZeneca; Bristol-Myers Squibb; Eisai; Iovance Biotherapeutics; Merck; Novartis; OncoSec; Pfizer; Replimune
Research Funding - Aeglea Biotherapeutics (Inst); Amgen (Inst); Asana Biosciences (Inst); BeiGene (Inst); BioMed Valley Discoveries (Inst); Compugen (Inst); Deciphera (Inst); Lilly (Inst); Merck (Inst); Moderna Therapeutics (Inst); Neon Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Strategia (Inst); Strategia (Inst); Viralytics (Inst)
 
Sarah Kin
Employment - Pulse Infoframe
 
Femida Hussein Gwadry-Sridhar
Employment - Pulse Infoframe
Leadership - Pulse Infoframe
 
Anthony M. Joshua
Stock and Other Ownership Interests - Pricilium Therapeutics
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); IQvia (Inst); Janssen Oncology (Inst); Merck Serono (Inst); Neoleukin Therapeutics (Inst); Novartis (Inst); Noxopharm (Inst); Pfizer (Inst); Sanofi (Inst)
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Janssen Oncology (Inst); Lilly (Inst); Lilly (Inst); Macrogenics (Inst); Mayne Pharma (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Richard D. Carvajal
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Aura Biosciences; Bristol-Myers Squibb/Medarex (Inst); Castle Biosciences; Chimeron Bio; Corvus Pharmaceuticals (Inst); Genzyme; Genzyme; IDEAYA Biosciences (Inst); Immunocore; InxMed; Iovance Biotherapeutics; Merck; Mirati Therapeutics (Inst); Novartis (Inst); Oncosec; Pfizer (Inst); Pierre Fabre; Plexxikon (Inst); PureTech; Regeneron; Regeneron; Rgenix; Roche/Genentech (Inst); Roche/Genentech (Inst); Sorrento Therapeutics; TriSalus Life Sciences
Speakers' Bureau - Bristol-Myers Squibb/Medarex
Research Funding - Amgen (Inst); Array BioPharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); IDEAYA Biosciences (Inst); Immunocore (Inst); Incyte (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst); Regeneron (Inst); Roche/Genentech (Inst)